Developer docs
API playgroundTry for free, no card

Search company profiles

AgomAb Therapeutics

Full company profile

uuid0000gs7

Namestring
AgomAb Therapeutics
Legal namestring
Agomab Therapeutics NV
Websiteurl
agomab.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company headquartered in Antwerp, Belgium, that develops disease-modifying therapies for fibro-inflammatory diseases characterized by organ fibrosis and scarring. Founded in 2017 and listed on Nasdaq under ticker AGMB following its February 2026 IPO, the company targets conditions with high unmet medical need — most notably Fibrostenosing Crohn's Disease (FSCD) and Idiopathic Pulmonary Fibrosis (IPF) — for which no approved pharmacological therapies currently exist and where existing standards of care rely heavily on surgical intervention or cause significant side effects.

The company's core technology is built around organ-restricted small molecule chemistry. Its lead candidate, ontunisertib (AGMB-129), is an oral, gastrointestinal-tract-restricted inhibitor of ALK5 (TGF-βR1) that is designed to act locally in the gut and then be rapidly inactivated in the liver to avoid the systemic toxicities (cardiovascular and large-vessel damage) that have historically limited ALK5 inhibitors; it is advancing into a Phase 2b NOV-RA study in FSCD after positive Phase 2a STENOVA data. AGMB-447 applies the same organ-restricted concept via an inhaled lung-restricted ALK5 inhibitor for IPF and is in Phase 1, while AGMB-101 is an HGF/MET receptor agonist antibody for liver cirrhosis that is Phase 1-ready. The portfolio is protected by composition-of-matter patents (including U.S. Patent No. 12,577,230 covering AGMB-447 through at least 2041) and FDA designations including Fast Track for ontunisertib and Orphan Drug Designation for AGMB-447.

AgomAb is pre-revenue and operates a traditional clinical-stage biopharmaceutical business model, financed entirely through equity capital rather than product sales. The company has raised approximately $300 million in private financing from investors including Pfizer, Sanofi, Fidelity, EQT Life Sciences, Pontifax, Andera Partners, and Boehringer Ingelheim Venture Fund, and added approximately $200 million in gross IPO proceeds in February 2026, taking year-end 2025 cash to €116.5 million and extending the runway into the first half of 2029. It operates three locations (Antwerp headquarters, an R&D laboratory in A Coruña, Spain acquired through the 2021 Origo Biopharma deal, and a U.S. subsidiary in Cambridge, MA), and employs between 51 and 100 staff, primarily in clinical development and regulatory affairs. R&D expenses scaled to €48.9 million in FY 2025 (from €39.3 million in FY 2024), producing a net loss of €62.5 million, with commercialization still multiple years away.

Short descriptiontext

AgomAb Therapeutics is a clinical-stage biopharmaceutical company developing organ-restricted small molecule and antibody therapies for fibro-inflammatory diseases, principally Fibrostenosing Crohn's Disease and Idiopathic Pulmonary Fibrosis. Pre-revenue, listed on Nasdaq since February 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAntwerp, Belgium
HQ citystring
Antwerp
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
fibrosis therapeutics, organ-restricted inhibitors, biopharmaceutical drug development, ALK5 inhibitors, clinical-stage biotechnology
Industry1 code
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceuticals - Fibrosis Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

AgomAb is a pre-revenue clinical-stage biopharmaceutical company with no approved products. The company generates no revenue and is funded through private financing and its February 2026 IPO. Future revenue will come from commercialization of drug candidates upon regulatory approval.

reuters.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AgomAb is a clinical-stage biopharmaceutical company developing disease-modifying small-molecule therapies that target fibrosis by modulating the TGF-β (via ALK5) and HGF/MET pathways, delivering candidates locally to the GI tract (Ontunisertib/AGMB-129 for Fibrostenosing Crohn's Disease), lungs (AGMB-447 for Idiopathic Pulmonary Fibrosis), and liver (AGMB-101 for liver cirrhosis). The company funds operations through equity financing and intends to commercialize its products through standard pharmaceutical distribution channels after regulatory approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 2a STENOVA trial completed with 103 FSCD patients showing positive safety signals and pharmacokinetic results supporting gut-restricted profile
+2 more records
Product overview1 text field

Agomab Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of disease-modifying therapies targeting fibro-inflammatory diseases with high unmet medical need. The company's core approach involves targeting the TGF-β pathway via ALK5 inhibition and the HGF/MET pathway. The lead product, ontunisertib (AGMB-129), is an oral GI-restricted ALK5 inhibitor for Fibrostenosing Crohn's Disease in Phase 2a. AGMB-447 is an inhaled lung-restricted ALK5 inhibitor for Idiopathic Pulmonary Fibrosis in Phase 1. AGMB-101 is a MET receptor agonist antibody targeting liver cirrhosis, Phase 1 ready. All candidates utilize organ-restricted delivery approaches to maximize local efficacy while minimizing systemic toxicity.

Product and service3 records
1Ontunisertib (AGMB-129)
CategoryClinical-stage small molecule drug candidate (oral ALK5 inhibitor) for fibro-inflammatory disease
Description

Selective and potent oral, gastrointestinal-tract-restricted small molecule inhibitor of ALK5 (TGFβR1) being developed for the treatment of Fibrostenosing Crohn's Disease (FSCD). Designed to act locally in the GI tract, enabling high exposure in target tissue and rapid hepatic inactivation to avoid systemic toxicities associated with systemic TGF-β inhibition. FDA Fast Track Designation granted; Phase 2b NOV-ERA trial in FSCD expected to initiate in the second half of 2026.

2AGMB-447
CategoryClinical-stage small molecule drug candidate (inhaled ALK5 inhibitor) for fibro-inflammatory disease
Description

Inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβR1) being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Designed to achieve high local exposure in lung tissue while being hydrolyzed and substantially inactivated upon systemic absorption to avoid cardiovascular toxicities. FDA Orphan Drug Designation granted in June 2024; U.S. Patent No. 12,577,230 covers composition of matter with protection through at least 2041. Phase 1 interim results in healthy subjects were positive; IPF patient cohort data expected in H2 2026.

3AGMB-101
CategoryPreclinical-stage biological drug candidate (HGF/MET receptor agonist antibody) for fibro-inflammatory disease
Description

Hepatocyte Growth Factor (HGF)-mimetic antibody designed to act through agonism of the MET receptor for the treatment of liver cirrhosis. Has demonstrated both antifibrotic and regenerative activity in preclinical models. Phase 1 ready.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing integrin-targeted therapies for fibrotic diseases including IPF (bexotegrast). Direct peer to AgomAb given shared fibrosis focus, similar clinical stage, and small-molecule approach to validated fibrosis pathways.

TypeDirect peer
Description

Biopharmaceutical company with a long-standing fibrosis franchise, including pamrevlumab (anti-CTGF) historically in development for IPF. Direct peer given shared focus on disease-modifying fibrosis therapeutics and clinical-stage profile.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics that target growth factor signaling, including TGF-β activation via latent myostatin and related pathways. Direct peer to AgomAb given shared TGF-β pathway focus and similar clinical-stage development model.

4Morphic Holding
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing oral integrin inhibitors for fibrotic diseases including IPF. Direct peer given shared small-molecule fibrosis approach, clinical-stage status, and IPF indication overlap.

5Blade Therapeutics
TypeEmerging player
Description

Clinical-stage company developing calpain inhibitors for fibrotic diseases, including IPF. Emerging peer with partial overlap in fibrosis mechanisms and indication focus, though targeting a different biological pathway than AgomAb's ALK5 inhibitors.

TypeBroad incumbent
Description

European biopharma with a historical fibrosis franchise, including the discontinued ziritaxestat IPF program. Broad incumbent peer given shared European roots, fibrosis R&D history, and prior clinical-stage development in IPF. Multiple AgomAb executives previously held senior roles at Galapagos.

TypeBroad incumbent
Description

Established biopharma with Tyvaso (treprostinil) approved for pulmonary hypertension associated with interstitial lung disease, including IPF. Broad incumbent peer operating in the IPF/pulmonary-fibrosis space, representing the kind of larger commercial-stage competitor AGMB-447 would face at launch.

8Boehringer Ingelheim
TypeBroad incumbent
Description

Global pharmaceutical company that markets Ofev (nintedanib), the leading approved IPF therapy, and is also an existing venture investor in AgomAb. Broad incumbent that is simultaneously a peer in IPF and a financial backer, creating both a competitive and alignment dimension.

TypeBroad incumbent
Description

Global pharmaceutical company that markets Esbriet (pirfenidone), the other leading approved IPF therapy. Broad incumbent peer representing the second entrenched standard-of-care competitor AGMB-447 would need to displace in IPF.

TypeEmerging player
Description

Clinical-stage oncology and fibrosis company developing small molecules targeting the TGF-β pathway. Emerging peer with meaningful mechanistic overlap to AgomAb's ALK5 program, though primarily focused on oncology applications.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AgomAb Therapeutics

Biopharmaceuticals - Fibrosis Therapeuticsagomab.com

AgomAb Therapeutics is a clinical-stage biopharmaceutical company developing organ-restricted small molecule and antibody therapies for fibro-inflammatory diseases, principally Fibrostenosing Crohn's Disease and Idiopathic Pulmonary Fibrosis. Pre-revenue, listed on Nasdaq since February 2026.

What AgomAb Therapeutics does

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company headquartered in Antwerp, Belgium, that develops disease-modifying therapies for fibro-inflammatory diseases characterized by organ fibrosis and scarring. Founded in 2017 and listed on Nasdaq under ticker AGMB following its February 2026 IPO, the company targets conditions with high unmet medical need — most notably Fibrostenosing Crohn's Disease (FSCD) and Idiopathic Pulmonary Fibrosis (IPF) — for which no approved pharmacological therapies currently exist and where existing standards of care rely heavily on surgical intervention or cause significant side effects.

The company's core technology is built around organ-restricted small molecule chemistry. Its lead candidate, ontunisertib (AGMB-129), is an oral, gastrointestinal-tract-restricted inhibitor of ALK5 (TGF-βR1) that is designed to act locally in the gut and then be rapidly inactivated in the liver to avoid the systemic toxicities (cardiovascular and large-vessel damage) that have historically limited ALK5 inhibitors; it is advancing into a Phase 2b NOV-RA study in FSCD after positive Phase 2a STENOVA data. AGMB-447 applies the same organ-restricted concept via an inhaled lung-restricted ALK5 inhibitor for IPF and is in Phase 1, while AGMB-101 is an HGF/MET receptor agonist antibody for liver cirrhosis that is Phase 1-ready. The portfolio is protected by composition-of-matter patents (including U.S. Patent No. 12,577,230 covering AGMB-447 through at least 2041) and FDA designations including Fast Track for ontunisertib and Orphan Drug Designation for AGMB-447.

AgomAb is pre-revenue and operates a traditional clinical-stage biopharmaceutical business model, financed entirely through equity capital rather than product sales. The company has raised approximately $300 million in private financing from investors including Pfizer, Sanofi, Fidelity, EQT Life Sciences, Pontifax, Andera Partners, and Boehringer Ingelheim Venture Fund, and added approximately $200 million in gross IPO proceeds in February 2026, taking year-end 2025 cash to €116.5 million and extending the runway into the first half of 2029. It operates three locations (Antwerp headquarters, an R&D laboratory in A Coruña, Spain acquired through the 2021 Origo Biopharma deal, and a U.S. subsidiary in Cambridge, MA), and employs between 51 and 100 staff, primarily in clinical development and regulatory affairs. R&D expenses scaled to €48.9 million in FY 2025 (from €39.3 million in FY 2024), producing a net loss of €62.5 million, with commercialization still multiple years away.

AgomAb Therapeutics firmographics

Firmographics
Name
AgomAb Therapeutics
Legal name
Agomab Therapeutics NV
Website
https://agomab.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
AgomAb Therapeutics is a clinical-stage biopharmaceutical company developing organ-restricted small molecule and antibody therapies for fibro-inflammatory diseases, principally Fibrostenosing Crohn's Disease and Idiopathic Pulmonary Fibrosis. Pre-revenue, listed on Nasdaq since February 2026.
Ownership category
akta.pro rank

AgomAb Therapeutics industry classification

Industry
Product category
Biopharmaceuticals - Fibrosis Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Fibrosis therapeutics
  • Organ-restricted inhibitors
  • Biopharmaceutical drug development
  • ALK5 inhibitors
  • Clinical-stage biotechnology

Where AgomAb Therapeutics is headquartered

Location

Headquarters

HQ city
Antwerp
HQ country
Belgium
HQ region
Europe

Offices3 records

Markets served

AgomAb Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Drug Development and Commercialization: AgomAb is a pre-revenue clinical-stage biopharmaceutical company with no approved products. The company generates no revenue and is funded through private financing and its February 2026 IPO. Future revenue will come from commercialization of drug candidates upon regulatory approval.

Go-to-market motion2 records

Marketing channels5 records

AgomAb Therapeutics product offering

Product offering

Core offering

AgomAb is a clinical-stage biopharmaceutical company developing disease-modifying small-molecule therapies that target fibrosis by modulating the TGF-β (via ALK5) and HGF/MET pathways, delivering candidates locally to the GI tract (Ontunisertib/AGMB-129 for Fibrostenosing Crohn's Disease), lungs (AGMB-447 for Idiopathic Pulmonary Fibrosis), and liver (AGMB-101 for liver cirrhosis). The company funds operations through equity financing and intends to commercialize its products through standard pharmaceutical distribution channels after regulatory approval.

Product overview

Agomab Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of disease-modifying therapies targeting fibro-inflammatory diseases with high unmet medical need. The company's core approach involves targeting the TGF-β pathway via ALK5 inhibition and the HGF/MET pathway. The lead product, ontunisertib (AGMB-129), is an oral GI-restricted ALK5 inhibitor for Fibrostenosing Crohn's Disease in Phase 2a. AGMB-447 is an inhaled lung-restricted ALK5 inhibitor for Idiopathic Pulmonary Fibrosis in Phase 1. AGMB-101 is a MET receptor agonist antibody targeting liver cirrhosis, Phase 1 ready. All candidates utilize organ-restricted delivery approaches to maximize local efficacy while minimizing systemic toxicity.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ontunisertib (AGMB-129) Selective and potent oral, gastrointestinal-tract-restricted small molecule inhibitor of ALK5 (TGFβR1) being developed for the treatment of Fibrostenosing Crohn's Disease (FSCD). Designed to act locally in the GI tract, enabling high exposure in target tissue and rapid hepatic inactivation to avoid systemic toxicities associated with systemic TGF-β inhibition. FDA Fast Track Designation granted; Phase 2b NOV-ERA trial in FSCD expected to initiate in the second half of 2026.
  • AGMB-447 Inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβR1) being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Designed to achieve high local exposure in lung tissue while being hydrolyzed and substantially inactivated upon systemic absorption to avoid cardiovascular toxicities. FDA Orphan Drug Designation granted in June 2024; U.S. Patent No. 12,577,230 covers composition of matter with protection through at least 2041. Phase 1 interim results in healthy subjects were positive; IPF patient cohort data expected in H2 2026.
  • AGMB-101 Hepatocyte Growth Factor (HGF)-mimetic antibody designed to act through agonism of the MET receptor for the treatment of liver cirrhosis. Has demonstrated both antifibrotic and regenerative activity in preclinical models. Phase 1 ready.

Quantifiable outcome

  • Phase 2a STENOVA trial completed with 103 FSCD patients showing positive safety signals and pharmacokinetic results supporting gut-restricted profile
  • +2 more outcomes

Companies that use AgomAb Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

AgomAb Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

AgomAb Therapeutics partnerships and signals

Strategic signal

Scale indicators13 records

Recent moves9 records

Expansion highlights7 records

AgomAb Therapeutics competitors and assessment

Company assessment

Direct peers

  • Pliant Therapeutics: Clinical-stage biopharmaceutical company developing integrin-targeted therapies for fibrotic diseases including IPF (bexotegrast). Direct peer to AgomAb given shared fibrosis focus, similar clinical stage, and small-molecule approach to validated fibrosis pathways.
  • FibroGen: Biopharmaceutical company with a long-standing fibrosis franchise, including pamrevlumab (anti-CTGF) historically in development for IPF. Direct peer given shared focus on disease-modifying fibrosis therapeutics and clinical-stage profile.
  • Scholar Rock: Clinical-stage biotech developing therapeutics that target growth factor signaling, including TGF-β activation via latent myostatin and related pathways. Direct peer to AgomAb given shared TGF-β pathway focus and similar clinical-stage development model.
  • Morphic Holding: Clinical-stage biopharmaceutical company developing oral integrin inhibitors for fibrotic diseases including IPF. Direct peer given shared small-molecule fibrosis approach, clinical-stage status, and IPF indication overlap.

Emerging players

  • Blade Therapeutics: Clinical-stage company developing calpain inhibitors for fibrotic diseases, including IPF. Emerging peer with partial overlap in fibrosis mechanisms and indication focus, though targeting a different biological pathway than AgomAb's ALK5 inhibitors.
  • Vivace Therapeutics: Clinical-stage oncology and fibrosis company developing small molecules targeting the TGF-β pathway. Emerging peer with meaningful mechanistic overlap to AgomAb's ALK5 program, though primarily focused on oncology applications.

Broad incumbents

  • Galapagos NV: European biopharma with a historical fibrosis franchise, including the discontinued ziritaxestat IPF program. Broad incumbent peer given shared European roots, fibrosis R&D history, and prior clinical-stage development in IPF. Multiple AgomAb executives previously held senior roles at Galapagos.
  • United Therapeutics: Established biopharma with Tyvaso (treprostinil) approved for pulmonary hypertension associated with interstitial lung disease, including IPF. Broad incumbent peer operating in the IPF/pulmonary-fibrosis space, representing the kind of larger commercial-stage competitor AGMB-447 would face at launch.
  • Boehringer Ingelheim: Global pharmaceutical company that markets Ofev (nintedanib), the leading approved IPF therapy, and is also an existing venture investor in AgomAb. Broad incumbent that is simultaneously a peer in IPF and a financial backer, creating both a competitive and alignment dimension.
  • Roche: Global pharmaceutical company that markets Esbriet (pirfenidone), the other leading approved IPF therapy. Broad incumbent peer representing the second entrenched standard-of-care competitor AGMB-447 would need to displace in IPF.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

AgomAb Therapeutics social profiles

Digital presence

AgomAb Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AgomAb Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

AgomAb Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

AgomAb Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AgomAb Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AgomAb Therapeutics

What does AgomAb Therapeutics do?

AgomAb is a clinical-stage biopharmaceutical company developing disease-modifying small-molecule therapies that target fibrosis by modulating the TGF-β (via ALK5) and HGF/MET pathways, delivering candidates locally to the GI tract (Ontunisertib/AGMB-129 for Fibrostenosing Crohn's Disease), lungs (AGMB-447 for Idiopathic Pulmonary Fibrosis), and liver (AGMB-101 for liver cirrhosis). The company funds operations through equity financing and intends to commercialize its products through standard pharmaceutical distribution channels after regulatory approval.

Is AgomAb Therapeutics a public or private company?

AgomAb Therapeutics is a public company. It is classified as public and is currently operating.

When was AgomAb Therapeutics founded?

AgomAb Therapeutics was founded in 2017. It employs 51 to 100 people.

Where is AgomAb Therapeutics based?

AgomAb Therapeutics is headquartered in Antwerp, Belgium, in the Europe region.

How does AgomAb Therapeutics make money?

One revenue line is on record: drug Development and Commercialization.

Who are AgomAb Therapeutics's main competitors?

Direct peers on record are Pliant Therapeutics, FibroGen, Scholar Rock and Morphic Holding. Emerging players are Blade Therapeutics and Vivace Therapeutics. Broad incumbents are Galapagos NV, United Therapeutics, Boehringer Ingelheim and Roche.

Does AgomAb Therapeutics have an API?

No public API is recorded for AgomAb Therapeutics.

What industry is AgomAb Therapeutics in?

AgomAb Therapeutics's product category is Biopharmaceuticals - Fibrosis Therapeutics. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StWe Think AgomAb Therapeutics (NASDAQ:AGMB) Can Afford To Drive Business GrowthAgomAb Therapeutics has a cash runway of about 4.4 years as of June 2026, with €252m cash and €57m annual burn. Its burn increased 13% over the past year, and covering another year's operations would require issuing shares representing 21% of its €267m market cap.MarketBeatAgomAb Therapeutics NV (NASDAQ:AGMB) Stock Has Consensus Target Price of $37.50 According to BrokeragesAgomAb Therapeutics has a Moderate Buy consensus from nine analysts, with an average 12-month price target of $37.50. Insiders bought 41,000 shares over the last quarter, and the stock opened at $9.05, trading below its 50-day moving average. The company expects a loss of about $1.83 per share for the current year.MarketBeatAgomAb Therapeutics (NASDAQ:AGMB) Director Purchases $88,800.00 in StockAgomAb Therapeutics director David Epstein bought 10,000 shares at $8.88 each, increasing his stake by 66.67%. The company's stock traded down 0.8% to $9.04, and analysts have a consensus 'Moderate Buy' rating with a $37.50 target.Investing.comAgomab Therapeutics stock rating reiterated at Buy by H.C. WainwrightH.C. Wainwright reiterated a Buy rating and $35 price target on Agomab Therapeutics after a fibroinflammation panel at UEG Week. The stock trades at $8.73, implying over 300% upside to the target, with Wall Street targets ranging from $28 to $60. The firm cited ontunisertib's potential for fibrostenosing Crohn's disease.American Banking and Market NewsAgomAb Therapeutics (NASDAQ:AGMB) Director Acquires $44,500.00 in StockDirector David Epstein acquired 5,000 shares of AgomAb Therapeutics at $8.90 each, increasing his stake by 50%. The company reported a loss of $0.46 per share for the quarter, and analysts have an average rating of Moderate Buy with a target price of $37.50.MarketBeatAgomAb Therapeutics (NASDAQ:AGMB) Director Buys 5,000 Shares of StockAgomAb Therapeutics director David Epstein bought 5,000 shares at $8.90 each on October 8th, increasing his stake by 50% to 15,000 shares. The stock rose 1.3% to $9.34, while analysts rate it a Moderate Buy with a $37.50 target.Markets DailyInsider Buying: AgomAb Therapeutics (NASDAQ:AGMB) CFO Purchases 10,000 Shares of Company StockAgomAb Therapeutics CFO Pierre Thadee Victor Kemula bought 10,000 shares on October 6th at $8.59 each, totaling $85,900. The stock opened at $8.84, and analysts have an average rating of Moderate Buy with a $37.50 target.Ticker ReportAgomAb Therapeutics (NASDAQ:AGMB) Stock: Insider Tim Jasper Knotnerus Acquires 6,000 SharesCEO Tim Jasper Knotnerus acquired 6,000 shares of AgomAb Therapeutics on October 5th at $8.48 per share, raising his direct ownership to 16,823 shares. The stock opened at $8.84, and analysts have a consensus "Moderate Buy" rating with a $37.50 target price.MarketBeatAgomAb Therapeutics (NASDAQ:AGMB) CEO Purchases 6,000 Shares of StockAgomAb Therapeutics CEO Tim Jasper Knotnerus purchased 6,000 shares on October 5th at $8.48 each, raising his stake by 55.44% to 16,823 shares. The company reported a loss of $0.46 per share for the quarter, and analysts have a consensus price target of $37.50.MarketBeatInsider Buying: AgomAb Therapeutics (NASDAQ:AGMB) CFO Purchases 10,000 Shares of Company StockAgomAb Therapeutics CFO Pierre Thadee Victor Kemula bought 10,000 shares on October 6th at $8.59 each, totaling $85,900. The stock opened at $8.84, and analysts rate it a Moderate Buy with an average target of $37.50.